参考文献/References:
[1]Follmann M,Ackerstaff J,Redlich G,et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (bay 1021189) for the treatment of chronic heart failure[J]. J Med Chem,2017,60(12):5146-5161.
[2]Sandner P. From molecules to patients:exploring the therapeutic role of soluble guanylate cyclase stimulators[J]. Biol Chem,2018,399(7):679-690.
[3]Friebe A,Sandner P,Schmidtko A. cGMP:a unique 2nd messenger molecule- recent developments in cGMP research and development[J]. Naunyn Schmiedebergs Arch Pharmacol,2020,393(2):287-302.
[4]Nakai T,Perl NR,Barden TC,et al. Discovery of IWP-051,a novel orally bioavailable sgc stimulator with once-daily dosing potential in humans[J]. ACS Med Chem Lett,2016,7(5):465-469.
[5]Zheng X,Zheng W,Xiong B,et al. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure:a systematic review and meta-analysis[J ]. Medicine (Baltimore),2018,97(41):e12709.
[6]Boettcher M,Gerisch M,Lobmeyer M,et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat,a soluble guanylate cyclase stimulator: results from preclinical and phase Ⅰ healthy volunteer studies[J]. Clin Pharmacokinet,2020,59(11):1407-1418.
[7]Coats AJS,Vericiguat for heart failure and the VICTORIA trial - the dog that didnt bark?[J]. Eur J Heart Fail,2020,22(4):576-577.
[8]Clark KAA,Velazquez EJ. Heart failure with preserved ejection fraction: time for a reset[J]. JAMA,2020,324(15):1506-1508.
[9]Breitenstein S,Roessig L,Sandner P,et al. Novel sGC stimulators and sGC activators for the treatment of heart failure[J]. Handb Exp Pharmacol,2017,243:225-247.
[10]Pieske B,Patel MJ,Westerhout CM,et al. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial[J]. Eur J Heart Fail,2019,21(12):1596-1604.
[11]Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2020,382(20): 1883-1893.
[12]Armstrong PW,Anstrom KJ,OConnor CM,et al. Vericiguat in heart failure with reduced ejection fractionreply[J]. N Engl J Med,2020,383(15):1497-1498.
[13]Aimo A,Pateras K,Stamatelopoulos K,et al. Relative efficacy of sacubitril-valsartan,vericiguat,and SGLT2 inhibitors in heart failure with reduced ejection fraction:a systematic review and network meta-analysis[J]. Cardiovasc Drugs Ther,2020?Oct 19. doi: 10.1007/s10557-020-07099-2.
[14]Ezekowitz JA,OConnor CM,Troughton RW,et al. N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart?failure with reduced ejection fraction study[J]. JACC Heart Fail,2020,8(11):931-939.
[15]Huynh K. Novel sGC stimulator improves outcomes in patients with HFrEF[J]. Nat Rev Cardiol,2020,17(6):320-321.
[16]Tsch?pe C,Pieske B.New therapy concepts for heart failure with preserved ejection fraction[J]. Herz,2015,40(2):194-205.
[17]Averbuch T,Van Spall HGC.Vericiguat reduced a composite of CV death or HF hospitalization in patients with HF and reduced LVEF[J]. Ann Intern Med,2020,173(6):JC30.
[18]Butler J,Lam CSP,Anstrom KJ,et al. Rationale and design of the VITALITY-HFpEF trial[J]. Circ Heart Fail,2019,12(5):e005998.
[19]Cunningham JW,Jhund PS.Vericiguat in heart?failure with reduced ejection fraction with high natriuretic peptides: a case of too little,too late?[J]. JACC Heart Fail,2020,8(11):940-942.
[20]Gheorghiade M,Greene SJ,Butler J,et al. Effect of vericiguat,a soluble guanylate cyclase stimulator,on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial[J]. JAMA,2015,314(21):2251-2262.
[21]Cleland JGF,Mueller C.What can we learn from SOCRATES:more questions than answers?[J]. Eur Heart J,2017,38(15):1128-1131.
[22]N?sheim T,How OJ,Myrmel T. Hemodynamic effects of a soluble guanylate cyclase stimulator,riociguat,and an activator,cinaciguat,during NO-modulation in healthy pigs[J]. J Cardiovasc Pharmacol Ther,2021,26(1):75-87.
[23]Chen Y,Zhu L,Fang Z,et al. Soluble guanylate cyclase contribute genetic susceptibility to essential hypertension in the Han Chinese population[J]. Ann Transl Med,2019,7(22):620.
[24]Brockunier L,Stelmach J,Guo J,et al. Soluble guanylate cyclase stimulators for the treatment of hypertension:discovery of MK-2947[J]. Bioorg Med Chem Lett,2020,30(21):127574.
[25]Dasgupta A,Bowman L,DArsigny CL,et al. Soluble guanylate cyclase:a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J]. Clin Pharmacol Ther,2015,97(1): 88-102.
[26]Sandner P,Berger P,Zenzmaier C.The potential of sGC modulators for the treatment of age-related fibrosis:a mini-review[J]. Gerontology,2017,63(3):216-227.
[27]Sandner P,Stasch JP. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators:a review of the preclinical evidence[J ]. Respir Med,2017,122(suppl 1):S1-S9.
[28]Krishnan SM,Kraehling JR,Eitner F,et al. The impact of the nitric oxide(NO)/soluble guanylyl cyclase(sGC) signaling cascade on kidney health and disease:a preclinical perspective[J]. Int J Mol Sci,2018,19(6):1712.
[29]Emdin M,Aimo A,Castiglione V,et al. Targeting cyclic guanosine monophosphate to treat heart?failure:JACC review topic of the week[J]. J Am Coll Cardiol,2020,76(15):1795-1807.
[30]Fabris E,Merlo M,Rapezzi C,et al. Sacubitril/valsartan: updates and clinical evidence for a disease-modifying approach[J]. Drugs,2019,79(14):1543-1556.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(8):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(8):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(8):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]石曈 黄淑田.维利西呱及其抗心力衰竭的研究进展[J].心血管病学进展,2023,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.003]
SHI Tong,HUANG Shutian.Vericiguat and Its Anti-Heart Failure[J].Advances in Cardiovascular Diseases,2023,(8):394.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.003]